Cytek Biosciences to acquire flow cytometry & imaging assets from Luminex for $46.5M

Cytek Biosciences, Inc.

Purchase price ~$46.5M cash; deal expected to close within 30 days; includes >7,000 installed instruments.
Acquires Amnis imaging and Guava flow cytometers; >60% of FCI employees are commercial, boosting Cytek's sales and service.
Acquisition aligns with DiaSorin's strategic priorities; Cytek expands global footprint and adds entry-level instrument options.
Cytek to host investor conference call Feb 13 at 4:30 PM ET; details at investors.cytekbio.com.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Cytek Biosciences, Inc. entered into Asset Purchase Agreement with Luminex Corporation valued at approximately $46.5 million in cash (effective 2023-02-13).

Action: entry
Agreement: asset purchase
Counterparty: Luminex Corporation
Value: approximately $46.5 million in cash
Effective: 2023-02-13

Exact text from the filing

On February 13, 2023, Cytek Biosciences, Inc. (the “Company”) entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Luminex Corporation (“Luminex”), pursuant to which the Company agreed to acquire certain assets relating to the business of manufacturing, marketing, selling, servicing and maintaining Amnis-, CellStream-, Guava- and Muse-branded instruments, and flow cytometry reagent products and services of Luminex (the “Business”) for a purchase price of approximately $46.5 million in cash.

View on SEC.gov

Browse all material agreements →

Cytek Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-035865

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.